( Not for submission under 37 CFR 1.99)

Application Number		10825898
Filing Date		2004-04-15
First Named Inventor	Boyle	, William J.
Art Unit		1644
Examiner Name	Schw	adron, Ronald B.
Attorney Docket Numb	er	A-451N IDS#2-090309

				U.S.	PATENTS	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6479635	B1	2002-11-12	Anderson et al.	
	2	6838262	B1	2005-01-04	Anderson et al.	
	3	7411050	B2	2008-08-12	Anderson	
	4	7449185	B2	2008-11-08	Yamaguchi et al.	
,	5	7527790	B2	2009-05-05	Yamaguchi et al.	
If you wish	to ac	ld additional U.S. Paten	t citatio	n information pl	ease click the Add button.	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20050003391	A1	2005-01-06	Anderson	

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10825898 Filing Date 2004-04-15 First Named Inventor Boyle, William J. 1644 Schwadron, Ronald B. A-451N Attorney Docket Number IDS#2-090309

Art Unit ( Not for submission under 37 CFR 1.99) Examiner Name

2 20080009014 Α1 2008-01-10 Anderson 3 20090004196 Α1 2009-01-01 Anderson et al. 4 20090017033 A1 2009-01-15 Anderson 5 20050208580 Α1 2005-09-22 Yamaquchi et al. 6 20070009520 Α1 2007-01-11 Yamaguchi et al. 7 20080187540 AΘ 2008-08-07 Yamaguchi et al. If you wish to add additional U.S. Published Application citation information please click the Add button. FOREIGN PATENT DOCUMENTS Pages, Columns, Lines Name of Patentee or Examiner Cite Foreign Document Country Kind Publication where Relevant Passages or Relevant Applicant of cited Initial\* No Number<sup>3</sup> Code2i Code4 Date Document Figures Appear Goto et al. (English 1 9626217 WO Α1 1996-08-29 equivalent EP 0 816 300) 2 9700318 wο Α1 1997-01-03 Roodman 3 9807840 wo Α1 1998-02-26 Nakagawa et al.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

 Application Number
 10825898

 Filling Date
 2004-04-15

 First Named Inventor
 Boyle, William J.

 Art Unit
 1644

 Examiner Name
 Schwadron, Ronald B.

STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)	Art Unit		1644	
(Tractor Submission ander or Of It 1.55)	Examiner Name	Schwadron, Ronald B.		
	Attorney Docket Numb	er	A-451N IDS#2-090309	

4	9846644	wo	A1	1998-10-22	Yamaguchi et al.	
5	9846751	wo	A1	1998-10-22	Boyle	
6	9849305	wo	A1	1998-11-05	Boyle et al.	
7	0874045	EP	A1	1998-10-28	Nakagawa et al.	
8	0117543	wo -	A2	2001-03-15	Dunstan	
9	0117543	wo	A3	2001-03-15	Dunstan	
10	0118203	wo	A1	2001-03-15	Dunstan et al.	
11	0162932	wo	A1	2001-08-30	Deshpande et al.	
12	0215846	wo	A2	2002-02-28	Sweet et al.	
13	03002713	wo	A2	2003-01-09	Boyle et al.	
14	0816380	EP	A1	1998-01-07	Goto et al.	

EFS Web 2.1.5

#### INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10825898				
Filing Date		2004-04-15				
First Named Inventor Boyle		, William J.				
Art Unit		1644				
Examiner Name Schw		adron, Ronald B.				
Attorney Docket Number		A-451N IDS#2-090309				

	_			V				
	15	0873998	EP '	A2	1998-10-28	Nishi et al.		
	16	0911342	EP	A1	1999-04-28	Yamaguchi et al.		
	17	11009269	JP ,		1999-01-19	Tsurugai et al.		o.
	18	9014363	wo	A1	1990-11-29	Langley et al.		
*	19	9634095	wo	A1	1996-10-31	Ni et al.		
	20	9828423	wo	A2	1998-07-02	Roodman et al.		
	21	9854201	wo	A1	1998-12-03	Ni et al.		
	22	9929865	wo	C2	1999-06-17	Choi et al.	ı	
	23	9965449	wo	A2	1999-12-23	Callahan et al.		
	24	9965495	wo	A1	1999-12-23	Callahan et al.		
If you wis	sh to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add buttor	1	
			NON-PATE	NT LITE	RATURE DO	CUMENTS	.,,,,,	

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10825898	3	
iling Date		2004-04-	15	
irst Named Inventor	Boy	le, William J.		
Art Unit		1644		
xaminer Name	Sch	wadron, Ror	nald B.	
ttorney Docket Numb	er	A-451N	IDS#2-090309	

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	O'Brien, E. A. et al., "Osteoprotegerin ligand regulates osteodast adherence to the bone surface in mouse calvaria", Biochem. Biochys. Res. Commun., 274: 281-290 (2000)	
	2	Oyajobi et al., "Therapeutic efficacy of a soluble receptor activator of nuclear factor kappa-B-igG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy", Cancer Res., 61: 2572-2578 (March 15, 2001)	
	3	Pelarson et al., "AMG162, A fully human monoclonal antibody against receptor activator of NF-Kappa B ligand (RANKL), rapidly and profoundly suppresses bone resorption in cynomolgus monkey", Internati. Bone and Mineral Society-Japan Bone and Mineral Society-Japan Bone and Mineral Society, 2003, Poster Session 2 "Osteoclasts", Osaka, Japan (June 6, 2003)	
	4	Reddi, A. H., "Bone morphogenesis and modeling: soluble signals sculpt osteosomes in the solid state", Cell, 89: 151-181 (1997)	
	5	Reiger et al., Glossary of Genetics and Cytogenetics, p. 17, Springer-Verlag Berlin Heidlberg, New York (1976)	
	6	Suda, T. et al., "Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families", Endocr. Rev., 20: 345-357 (1999)	
	7	Takada et al., "A simple method to assess osteoclast-mediated bone resorption using unfractionated bone cells", Bone and Mineral, 17: 347-359 (1992)	
	8	Takeyama, S. et al., "Low calcium environment effects osteoprotegerin ligand/osteoclast differentiation factor", Biochim. Biophys. Res. Commun., 276: 524-529 (2000)	
	9	Teng, Y. A. et al., "Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection", J. Clin. Invest., 106: 749-752 (2000)	
	10	Tsuda et al., "Isolation of a novel cutokine from human fibroblasts that specifically inhibits osteoclastogenesis", Biochemical and Biophysical Research Communications, 234(1): 137-142 (1997)	

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number		10825898
Filing Date		2004-04-15
irst Named Inventor	Boyle	e, William J.
Art Unit		1644
Examiner Name	Schw	vadron, Ronald B.
Attorney Docket Numb	or	A-451N IDS#2.000300

( Not for submission under 37 CFR 1.99)

11	Udagawa, N. et al., "Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but no macrophage colony-stimulating factors", Bone, 25: 517-523 (1999)	
12	/ Watanabe et al., "Interlukin-4 as a potent inhibitor of bone resorption", Biochemical and Biophysical Research Communications, 172(3): 1035-141 (1990)	
13	Willard, D. et al., "Expression, purification, and characterization of the human receptor activator of NF-kappaB ligand (RANKL) extracellular domain", Protein Expr. Purif., 20: 48-57 (2000)	
14	Wong et al., "The TRAF Family of Signal Transducers Mediates NF-xB Activation by the TRANCE Receptor", J. Biol. Chem., 273(43): 28355-28359 (1998)	
15	Yoneda et al., "Suramin suppresses hypercaloemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer", Cancer Research, 55: 1989-1993 (1995)	
16	Zhang et al., "Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways", J. Biol. Chem., 276(1): 583-588 (January 5, 2001)	
17	INTENTIONALLY LEFT BLANK	
18	Abbas, A. K. et al., Cellular and Molecular Immunology, W.B. Saunders Company, 2nd Edition, (1994) (TABLE OF CONTENTS ONLY)	
19	Bork, P., "Powers and pitfalls in sequence analysis: the 70% hurdle", Genome Res., 10: 398-400 (2000)	
20	Bruggermann et al., "Strategies for expressing human antibody repertoires in transgenic mice", Immunology Today, 17(8): 391-397 (1996)	
21	Doerks et al., "Protein annotation: detective work for function prediction", Trends in Genetics, 14(6): 248-250 (1998)	

EFS Web 2.1.5

#### INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10825898				
Filing Date		2004-04-15				
First Named Inventor Boyle,		e, William J.				
Art Unit		1644				
Examiner Name Schwi		vadron, Ronald B.				
Attorney Docket Numi	er	A-451N IDS#2-090309				

	22	Emery, V. G. et al., "Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL", J. Biol. Chem., 273(23): 14363-14367 (1998)	
	23	Imgenex product use sheet, Catalog No: IMG-185B, Clone: 12A380, Monoclonal antibody to TRANCE/RANKL/OPGL/ ODF conjugated with Biotin, Website: http://www.imgenex.com/antibody_details.php?catalog=IMG-185B, downloaded 01/26/06.	
	24	Skolnick et al., "From genes to protein structure and function: novel applications of computational approaches in the genomic era", Trends in Biotech, 18(1): 34-39 (2000)	
	25	Stressgen product use sheet for product AAM-425AF, anti-TRANCE/RANKL, clone 12A668, revised 6/27/05.	
	26	Yang et al., "Human group-specific component (Gc) is a member of the albumin family", Proc. Natl. Acad. Sci., USA, 82: 7894-7998 (1985)	
	27	Boyle v. Gorman and Mattson, Board of Patent Appeals and Interferences, Interference No. 104,336, Paper No. 39	
	28	Camerini et al., "The T Cell Activation Antigen CD27 is a Member of the Nerve Growth Factor/Tumor Necrosis Factor Receptor Gene Family", J. Immunol., 147: 3165-3169 (1991)	
	29	. Caux et al., "Activation of Human Dendritic Cells through CD40 Cross-Linking", J. Exp. Med., 180: 1263-1272 (1994)	
	30	Crooke, :An overview of progress in antisense therapeutics", Antisense & Nucleic Acid Drug Dev., 8: 115-122 (1998)	
	31	Durkop et al., "Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease", Cell, 68: 421-427 (1992)	
If you wi	sh to a	dd additional non-patent literature document citation information please click the Add button	

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

pplication Number		10825898	
iling Date		2004-04-15	
irst Named Inventor	Boyle, William J.		
rt Unit		1644	
xaminer Name	Schwadron, Ronald B.		
ttorney Docket Number		A-451N IDS#2-090309	

EXAMINER SIGNATURE					
Examiner Signature	/Ronald Schwadron/	Date Considered	09/15/2009		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Α

1 See Kind Codes of USPTO Patent Documents at <a href="https://www.uSPTO.GOV">www.uSPTO.GOV</a> or MPEP 901.04.3 Enter office that issued the document, by the two-tester code (MPO Standard ST3.).9 "For Japanese patent document, be indication of the year of the reign of the Emperor must pre-ded the serial number of the patent document." 4 Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST.16 if possible. 4 Spatients to piace a check mark here if English language translation is attached.